EUCTR2021-004277-31-BE进行中（未招募）1 期
A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV16 positive carcinoma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age greater than or equal to 18 years.
- •Cohort 1: Confirmed recurrent and/or metastatic (R/M) HPV16+ cancer (including oropharyngeal, cervical, vulval, vaginal, anal, penile cancer) based on expression analysis of HPV type 16 in tumor tissue by HPV 16 ISH or HPV E1 PCR. Cancer must have progressed after at least 1 available standard therapy for incurable disease, or the subject is intolerant to or refuses standard therapy(ies) or has a tumor for which no standard therapy(ies) exists.
- •Cohort 2: Confirmed R/M HPV16+ oropharyngeal (based on expression of HPV type 16 in tumor tissue by HPV 16 ISH or HPV E1 PCR), and eligible for 1st line monotherapy pembrolizumab treatment OR Subjects with confirmed R/M anogenital HPV16+ cancer (cervical, anal, penile, vulvar, or vaginal cancer) confirmed by HPV 16 ISH or HPV E1 PCR. Maximum 2 previous systemic therapies with chemotherapy and/or targeted therapies for recurrent and/or metastatic disease, no prior aPD(L)-1, and a CPS>1.
- •- At least one measurable lesion, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1; Eisenhauer et al, 2009).
- •- Subjects entering the study will need to consent to provide a tumor tissue sample (formalin fixed paraffin embedded blocks/slides less than 2 months old or older only upon approval by Sponsor) or a fresh biopsy.
- •- Adequate hematologic function
- •- Adequate renal and hepatic function
- •- Adequate coagulation parameters
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 33
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 33
排除标准
- •- Grade 3 or 4 peripheral neuropathy at time of screening.
- •- Subjects with active or history of autoimmune disease or immune deficiency.
- •- Subjects with serious intercurrent chronic or acute illness.
- •- Subjects who have had a splenectomy.
- •- Subjects with known hypersensitivity to any component of the Investigational Medicinal Product and/or pembrolizumab (Cohort 2).
- •- Prior treatment with HPV therapeutic vaccines. Subjects may have received a preventive HPV vaccine.
- •- Subjects who received an mRNA LNP based vaccine less than 30 days prior to start of the therapy.
- •Additional Criteria for Cohort 2:
- •- Chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks prior to start of treatment with EI-201 for subjects with anogenital cancers.
- •- Subjects who have received prior systemic therapy and/or active immunotherapy for HNSCC, such as antigen loaded dendritic cells, chimeric antigen receptor (CAR) T cells, or checkpoint inhibitors are excluded.
研究者
相似试验
尚未招募
不适用
A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV16 positive carcinomaNL-OMON56720eTheRNA immunotherapies10
进行中（未招募）
1 期
A study to test safety and efficacy of treatment with ipilimumab and nivolumab in patients suffering from melanoma having 4 and more brain metastasesPatients with stage IV melanoma and four or more symptomatic brain metastases, who are not eligible for surgery or radiosurgeryMedDRA version: 21.1 Level: LLT Classification code 10025655 Term: Malignant melanoma of skin System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10025671 Term: Malignant melanoma stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: LLT Classification code 10006128 Term: Brain metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10025650 Term: Malignant melanoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10027480 Term: Metastatic malignant melanoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004614-10-DEniversity Hospital Tübingen68
进行中（未招募）
不适用
A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acute Respiratory Distress Syndrome.EUCTR2008-000140-13-GBFaron Pharmaceuticals Limited
已完成
1 期
Heat-labile toxin (LT) safety study in the elderlyEnterotoxigenic Escherichia coli (ETEC) infectionInfections and InfestationsOther bacterial intestinal infectionsISRCTN27362371Iomai Corporation (USA)40
已完成
1 期
A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects.CTRI/2019/04/018635Human Biologicals Institute55